Research Study

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome
Principal Investigator 
Christopher Fordyce

Overview

Body Locations and Systems 
ClinicalTrials.gov# 
NCT03473223
Status 
Recruiting
Study Start/End 
Jun 29, 2018 to Oct 31, 2021
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Shirley Lim, Research Coordinator
Phone 
604-875-4065
Email Address 
shirley.lim@vch.ca
Purpose of Study 

The purpose of this study is to test the safety and efficacy of a new drug (CSL112, also known as Apolipoprotein A-I) in participants with acute coronary syndrome.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.